Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	3.85M 3.34M 3.11M 2.86M 5.41M 366M 5.47M 36.71M 14.35M 183M 14.44M 14.13M 606M	P/E 2024	-0.33x	P/E 2025	-0.12x
Enterprise Value	-379K -329K -306K -282K -532K -36.01M -538K -3.61M -1.41M -18M -1.42M -1.39M -59.64M	EV / Sales 2024	-551,308x	EV / Sales 2025	289,759x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

07-29	Scisparc Ltd. Announces Establishment of Scientific Advisory Board	CI
04-30	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-29	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-17	Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression Therapy	CI
03-16	Scisparc Neurothera Labs- Clearmind Medicine collaboration leads to patent application for depression therapy	RE
03-10	Clearmind Medicine Inc Announces Publication of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Metabolic Dysfunction-Associated Steatotic Liver Disease	CI
03-10	Top Premarket Decliners	MT
02-12	SciSparc Ltd. announced that it expects to receive $9 million in funding	CI
01-26	Neurothera Labs Inc. completed the acquisition of Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd.	CI
01-13	SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal	MT
12-31	SciSparc Ltd.'s Equity Buyback announced on July 7, 2022, has expired.	CI
12-01	Scisparc plans on entering the multi-billion-dollar GERD device market with acquisition of an approved IP portfolio	RE
11-26	Scisparc to acquire treasury of patents for innovative medical endoscopy systems	RE

07-31	SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics	GL
07-30	SciSparc, Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company	AQ
07-29	SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company	GL
07-27	SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity	GL
07-15	SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome	GL

Manager	Title	Age	Since
Oz Adler CEO	Chief Executive Officer	39	10/01/2022
Amitay Weiss CEO	Chief Executive Officer	62	21/08/2020
Adi Zuloff-Shani CTO	Chief Tech/Sci/R&D Officer	56	08/02/2016

Director	Title	Age	Since
Amitay Weiss CHM	Chairman	62	10/01/2022
Itschak Shrem CHM	Chairman	79	21/09/2025
Lior Vider BRD	Director/Board Member	50	21/08/2020

Therapix Biosciences Ltd. Stock Nasdaq

Stocks

US88339A2033

Pharmaceuticals

Valuation: Therapix Biosciences Ltd.

Latest news : Therapix Biosciences Ltd.

Press Releases: Therapix Biosciences Ltd.

News in other languages: Therapix Biosciences Ltd.

Quotes and Performance

Managers and Directors: Therapix Biosciences Ltd.

Generic Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THERAPIX BIOSCIENCES LTD.	-48.90%	-.--%	-	-	4.1M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.03%	-0.64%	+19.64%	+72.44%	49.43B
OTSUKA HOLDINGS CO., LTD.	-0.04%	+4.17%	+61.59%	+128.85%	38.54B
CIPLA LIMITED	-0.98%	+1.07%	-3.64%	+20.69%	12.5B
ZYDUS LIFESCIENCES LIMITED	+0.80%	+2.80%	+17.85%	+73.91%	11.73B
KRKA, D. D.	-1.33%	-0.95%	+31.06%	+132.74%	9.09B
ONO PHARMACEUTICAL CO., LTD.	-0.89%	-8.21%	+35.61%	-16.04%	7.01B
GEDEON RICHTER	+0.17%	+2.31%	+15.24%	+34.04%	6.86B
GLENMARK PHARMACEUTICALS LIMITED	-0.22%	+1.85%	+7.23%	+176.90%	6.6B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+2.65%	+3.65%	-31.83%	+14.90%	5.48B
Average	-4.89%	+0.92%	+16.97%	+70.94%	16.36B
Weighted average by Cap.	-0.10%	+0.74%	+27.29%	+83.20%

	2024	2025
Net sales	1.31 1.13 1.06 0.97 1.84 124.23 1.86 12.47 4.87 62.1 4.9 4.8 205.77	0.86 0.74 0.69 0.64 1.2 81.42 1.22 8.17 3.19 40.7 3.21 3.14 134.87
Net income	-6.28M -5.46M -5.09M -4.67M -8.84M -598M -8.94M -59.98M -23.45M -299M -23.6M -23.08M -990M	-12.18M -10.58M -9.86M -9.06M -17.13M -1.16B -17.32M -116M -45.44M -579M -45.74M -44.73M -1.92B
Net Debt	-2.01M -1.75M -1.63M -1.5M -2.83M -191M -2.86M -19.19M -7.5M -95.62M -7.55M -7.39M -317M	-4.22M -3.67M -3.42M -3.14M -5.94M -402M -6.01M -40.33M -15.76M -201M -15.87M -15.52M -666M